New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

Description

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof Karam Kostner

A/Prof Karam Kostner

LDL Management – Why it is Important

A/Prof Ralph Audehm

A/Prof Ralph Audehm

Navigating Expanded PBS Access to SGLT2i in General Practice

Prof Deborah Bateson

Prof Deborah Bateson

Cervical Cancer Screening 2025

Clinical A/Prof Greg Katsoulotos

Clinical A/Prof Greg Katsoulotos

Asthma Cases – When to Use Dual vs Triple Therapy

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Paul Van Buynder

expert

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland

Date published: 25 July 2023